Penn study finds immunotherapy reduces cardiac fibrosis and restores heart function in mice after cardiac injury CAR T-cell therapy, a rapidly emerging form of immunotherapy using patients’ own cells to treat certain types of cancers, may be a viable treatment option for another life-threatening condition: heart disease. In a first-of-its-kind study, published today in Nature, researchers
The inhibitory receptors PD-1, Tim-3, and Lag-3 are highly expressed on tumor-infiltrating lymphocytes and compromise their antitumor activity. For efficient cancer immunotherapy, it is important to prevent chimeric antigen receptor T (CAR-T)-cell exhaustion. Here we downregulate these three checkpoint receptors simultaneously on CAR-T cells and that show the resulting PTL-CAR-T cells undergo epigenetic modifications and better control
Source Il Messaggero Matilde Leonardi, director of the Coma Research Center of the Besta Neurological Institute in Milan and a member of the Italian Society of Neurology, wants to be immediately clear. “The news about the former pilot is only fueling false hopes and deluding patients’ families.” Why is she so convinced that this therapy
The Italian biotech Genenta Science, a spin-out from San Raffaele Hospital has raised €13.2M in a private round to fund two ongoing phase I/II trials of its stem cell therapy Temferon for blood and brain cancer. Genenta Science will use the money to fund two European phase I/II trials, which the company launched in March. One
Tokyo Medical and Dental University(TMDU)-led study published in Nature shows that epidermal stem cells in the skin compete with each other to eliminate stressed, unfit cells; this maintains skin youthfulness, but with time also causes the skin to age. Aging is a process that results from the accumulation of damage due to failed repair and
Source https://www.sciencedirect.com/science/article/abs/pii/S002432051930757X?via%3Dihub&elqTrackId=b210a4797cc6484b94cf773fe330c747&elq=012dbc43f12c4386bdd3fa0ea93bb255&elqaid=26027&elqat=1&elqCampaignId=10598 Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system (CNS). In attempt to identify an appropriate treatment for improving the neurological symptoms and remyelination process, autologous and allogenic transplantation of mesenchymal stem cells (MSCs) have been introduced as an effective therapeutic strategy in MS. MSCs are a heterogeneous
Background and Purpose— Stroke is a leading cause of long-term disability. Limited treatment options exist for patients with chronic stroke and substantial functional deficits. The current study examined safety and preliminary efficacy estimates of intravenous allogeneic mesenchymal stem cells in this population. Methods— Entry criteria included ischemic stroke >6 months prior and substantial impairment (National
The majority of marketing authorizations granted through two expedited assessment pathways in Europe are based on non-validated surrogate endpoints rather than clinical outcomes, according to a study published September 10 in the open-access journal PLOS Medicine by Patricia McGettigan of Queen Mary University of London, and colleagues. The approval of new pharmaceutical products addressing an unmet need
Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed expectations, driving an ever-expanding number of clinical trials and the first US Food and Drug Administration approvals of cell therapies for the treatment of cancer. This experience has illuminated some generalizable requirements for CAR T cell efficacy as well as the interplay
A new study released today in STEM CELLS demonstrates that mesenchymal stromal cells (MSCs) expanded from adipose tissue (ASC) outperform those expanded from bone marrow (BM-MSCs). A new study released today in STEM CELLS demonstrates that mesenchymal stromal cells (MSCs) expanded from adipose tissue (ASC) outperform those expanded from bone marrow (BM-MSCs). Importantly, while several
